In preclinical studies, enapotamab vedotin exhibited significant single-agent activity in PDX NSCLC models expressing AXL, EGFR mutant, and EGFR inhibitor resistance (98). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.